Início › Mieloma Múltiplo › Indiana
Ensaios clínicos de Mieloma Múltiplo em Indiana
19 estudos para Mieloma Múltiplo estão buscando participantes em locais em Indiana.
Cidades em Indiana
Texto oficial do estudo (Inglês)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07582432A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Franciscan Health, Indianapolis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Indiana University, Indianapolis
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Genesis Medical Research, Dyer
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07477587A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
RecrutandoFase 2
Idades 12 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Indiana University - Purdue, Indianapolis
RecrutandoEstudo observacional
2 Months · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT00900198MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Indiana University, Indianapolis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Indiana University Health, Indianapolis
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07284758A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
- Franciscan St. Francis Health /ID# 280928, Indianapolis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Indiana University Health Simon Cancer Center, Indianapolis
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de jul. de 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- e mais 8
RecrutandoFase 3
Todas as idades · Todos os sexos · Atualizado em 10 de jun. de 2026 · NCT05561387cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 40 e acima · Todos os sexos · Atualizado em 20 de jan. de 2026 · NCT05366881The Indiana Myeloma Registry
- Indiana University Simon Cancer Center, Indianapolis
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 10 de nov. de 2025 · NCT03616483Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.